Platinum Industries Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
PLATIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Platinum Industries reported Q3 FY26 (Dec 31, 2025) results with standalone revenue from operations up ~30.8% YoY at ₹1,026.20 million and consolidated revenue up ~12% at ₹1,046.68 million. Standalone profit after tax grew ~18.4% YoY to ₹129.26 million, while consolidated PAT rose ~7% to ₹123.28 million for the quarter. However, for the nine-month period, standalone PAT fell ~11.6% YoY to ₹375.78 million and consolidated PAT dropped ~16.9% to ₹363.87 million, partly weighed by an exceptional loss of ₹5.17 million related to a July 2025 fire at subsidiary Platinum Polymers & Additives. The statutory auditor (PKF Sridhar & Santhanam LLP) issued a 'Qualified Conclusion' on both standalone and consolidated results, flagging uncertainty over recognition of an insurance receivable of ₹98.19 million. The board also approved incorporation of a new subsidiary, 'Rivadu Lifesciences Private Limited', to enter the pharmaceuticals and life-sciences segment with an initial capital of ₹25 lakh.
Strong quarterly topline growth is positive, but the qualified auditor opinion and ongoing uncertainty over the ₹98.19 million insurance claim are near-term concerns for shareholders. The move into pharma/life-sciences through a new subsidiary signals diversification, which could be a long-term positive but adds execution risk.